Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds
Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests
Ask the Expert: CBD Oil and Sjögren’s
Ask the Expert, Symptoms, Treatment — Aug 12, 2020
OMRF needs participants for Sjögren’s Syndrome study
Partnership to progress treatments for Sjogren’s syndrome
The University of Queensland and global biotechnology company CSL Limited
Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy
Two Projects Using Hydrogel Biomaterials to Stimulate Tissue Regeneration Move Forward with New Funding
Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome
Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome
MINNEAPOLIS, MN, USA, July 7, 2020 /EINPresswire.com/ — Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs.
The BAFF target was discovered by Reshmi Parameswaran, PhD, an assistant professor at the Case Western Reserve School of Medicine and a faculty member in the Division of Hematology and Oncology, Department of Medicine, and the Seidman Cancer Center at University Hospitals (UH) in Cleveland.
Luminary intends to conduct IND-enabling non-clinical studies to support two clinical trials with its novel and proprietary non-viral autologous BAFF CAR-T (LMY-920) to treat Mantle Cell Lymphoma and Sjogren’s Syndrome. This BAFF target is unique in that it binds to three distinct receptors (BAFF, BCMA, and TACI). Additionally, this BAFF target avoids early B-Cells while targeting more mature B-Cells that express one of three antigens.
New research published in Nature’s Laboratory Investigation shows that CP-25 “increased saliva flow, alleviated the salivary gland indexes, and improved tissue integrity” in a mouse model of primary Sjogren’s syndrome.
Researchers “identified the underlying mechanisms of the therapeutic effect of CP-25 and provided an experimental foundation for CP-25 as a potential drug in the treatment of the human autoimmune disorder pSS [primary Sjögren’s syndrome].”
The study titled, CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration, was published on July 3, 2020 and funded by the National Nature Science Foundation of China, the Provincial Natural Science Research Project of Anhui Province, and the Key Projects of Anhui Province University Outstanding Youth Talent Fund.
Subscribe to email updates about CP-25 and other promising new treatments for Sjogren’s syndrome. (Free. One email per week. No spam.)
Comments, questions, feedback? Send an email to firstname.lastname@example.org and say hello.
How the hydroxychloroquine (HCQ) shortage highlights Sjogren’s neglect
Updated: 4 hours ago
The 2020 Sjögren’s Foundation National Patient Conference is going Virtual!
June 26 & June 27, 2020
Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome
Targeted Approach for Tackling Sjögren’s Syndrome
Small molecules restore salivary function in mice
Abatacept Fails Clinical Trial for Sjögren’s Syndrome
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome
– Topline Results Expected Q2 2020
– Study designed to support approval pathway in the U.S. and other major markets
Jan 21, 2020, 09:00 ET
HOD HASHARON, Israel, Jan. 21, 2020 /PRNewswire/ — Wize Pharma, Inc. (OTCQB: WIZP) (“Wize”), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed enrolment in its Phase IV clinical trial of its eye drop formula to evaluate the efficacy of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome.
Potential Sjogren’s Therapy LOU064 Shows Promise in Early Lab Studies, Healthy Volunteers
Hope for patients with rare Sjögren’s syndrome
The Challenge of Identifying Sjogren’s Syndrome
The main symptoms — dry eyes and mouth, fatigue and limb pain — are common complaints associated with any number of health problems.
AT-RvD1 Restores Function of Salivary Glands, Decreases Harmful T-cells in Mouse Model of Sjögren’s